射血分数保留性心力衰竭的治疗进展

Therapeutic Options for Heart Failure with Preserved Ejection Fraction

射血分数保留性心力衰竭异质性强,存在功能和结构损伤的多样性,逐渐成为心力衰竭的主要形式。由于缺乏充分的循证医学证据,也缺乏统一的治疗指南,临床医生面临着巨大的挑战,是心脏病学亟需解决的问题。现将射血分数保留性心力衰竭的最新研究与潜在的治疗靶点联系起来,从血流动力学及分子细胞水平综述该病的治疗进展。

The heterogeneity of heart failure with preserved ejection fraction(HFpEF)is strong,and there is diversity of functional and structural damages.Thus,it's becoming the dominant form of heart failure.Because of the lack of the evidence of evidence-based medicine and a consensus recommendation,clinicians are facing enormous challenges,which makes it a pressing issue in Cardiology today.Recent research on HFpEF has been linked to potential therapeutic targets,and advances in the treatment of HFpEF at the hemodynamics and molecular cellular levels are reviewed in this article.